The Effect of Intrinsic Efficacy on Opioid Tolerance
Open Access
- 1 May 1995
- journal article
- laboratory investigations
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 82 (5) , 1226-1236
- https://doi.org/10.1097/00000542-199505000-00018
Abstract
Background: The intrinsic efficacy of opioid analgesics has been suggested to play a role in the development of tolerance to these agents. However, the effect of differences in dosing protocol on tolerance to opioid analgesics of high or low efficacy has not been addressed. Therefore, the effect of opioid intrinsic efficacy on tolerance in mice was determined in protocols of continuous and intermittent administration of equieffective doses of opioid agonists. Methods: Initial antinociceptive median effective doses (ED50s) for five opioid agonists that vary in intrinsic efficacy were estimated in untreated mice. Groups of mice received continuous infusions of morphine, fentanyl, or etorphine for 72 h or 7 days from osmotic minipumps implanted subcutaneously. The infusion doses were calculated as multiples of the initial antinociceptive ED50. An inert placebo was implanted subcutaneously in controls. At the end of treatment, the pumps and placebos were removed, and 4-24 h later, mice were tested in dose-response studies (tail flick) using the same drug that had been chronically administered. In another study using intermittent dosing, mice received subcutaneous injections every 24 h for 3 days of saline or morphine, etorphine, fentanyl, oxycodone, or meperidine, or received subcutaneous injections every 24 h for 7 days of saline or morphine, etorphine, or fentanyl. Daily doses were calculated as multiples of the initial antinociceptive ED50. Twenty-four hours after the last injection, mice were tested in dose-response studies. Results: High-intrinsic-efficacy compounds (e.g., etorphine and fentanyl) produced less tolerance than a lower-intrinsic-efficacy drug (morphine) in 72-h and 7-day infusion studies. Tolerance for all compounds after intermittent treatment with equieffective doses was similar, and intrinsic efficacy had no effect on the magnitude of tolerance after intermittent dosing. Conclusions: These results indicate that the intrinsic efficacy of opioid analgesics is inversely related to the degree of tolerance after continuous infusion, but that intrinsic efficacy does not significantly affect tolerance after once-daily intermittent administration of these agents. These findings may be of clinical utility in understanding the development of tolerance to the antinociceptive effects of opioids.Keywords
This publication has 9 references indexed in Scilit:
- Is disease progression the major factor in morphine ‘tolerance’ in cancer pain treatment?PAIN®, 1993
- Cancer pain management current strategyCancer, 1993
- Magnitude of Acute Tolerance to Opioids Is Not Related to Their PotencyAnesthesiology, 1991
- Differential Cross-tolerance Between Intrathecal Morphine and Sufentanil in the RatAnesthesiology, 1990
- Administration of Intraspinal Morphine Sulfate for the Treatment of Intractable Cancer PainNeurosurgery, 1986
- Evidence for a single opioid receptor type on the field stimulated rat vas deferensLife Sciences, 1981
- Tissue Redistribution of Fentanyl and Termination of Its Effects in RatsAnesthesiology, 1981
- Chronic morphine administration: Plasma levels and withdrawal syndrome in ratsPharmacology Biochemistry and Behavior, 1976
- Receptor Occupancy and Tissue ResponseNature, 1956